 Now, once it is out, how widely will it be available? I know there have already been calls to ensure that low- and middle-income countries can get hold of it. So that's a really good question. So, I mean, at the moment, Gilead is charging more than $42,000 per year for linacapavir to patients in the United States who are receiving it as treatment. If that's the price that it's set at as a prevention tool in sub-Saharan Africa or other